Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Neurocrine Biosciences, Inc shares valued at $61,695 were sold by Delaet Ingrid on Jul 10 ’25. At $135.00 per share, Delaet Ingrid sold 457 shares. The insider’s holdings dropped to 4,730 shares worth approximately $0.63 million following the completion of this transaction.
Also, Onyia Jude sold 59,819 shares, netting a total of over 7,803,688 in proceeds. Following the sale of shares at $130.46 each, the insider now holds 18,289 shares.
Before that, INGRID DELAET had added 457 shares to its account. In a trade valued at $61,014, the Officer bought Neurocrine Biosciences, Inc shares for $133.51 each.
As published in their initiating research note from Goldman on July 10, 2025, Neurocrine Biosciences, Inc [NBIX] has been a Buy and the price target has been revised to $182. Analysts at Needham upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid April. As of April 14, 2025, RBC Capital Mkts has increased its “Sector perform” rating to a “an Outperform” for NBIX. Earlier on February 11, 2025, Deutsche Bank initiated its rating. Their recommendation was “a Hold” for NBIX stock.
Analyzing NBIX Stock Performance
On last trading session,, Neurocrine Biosciences, Inc [NASDAQ: NBIX] rose 1.71% to $133.48. The stock’s lowest price that day was $131.07, but it reached a high of $134.24 in the same session. During the last five days, there has been a drop of approximately -0.02%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -9.46%. Shares of the company reached a 52-week high of $154.61 on 01/30/25 and a 52-week low of $84.23 on 04/09/25.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 131.62, which, if violated, would cause prices to drop to 129.75. In the upper region, resistance lies at 134.80. The next price resistance is at 136.11. RSI (Relative Strength Index) is 62.24 on the 14-day chart, showing neutral technical sentiment.
Is Neurocrine Biosciences, Inc subject to short interest?
Stocks of Neurocrine Biosciences, Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.53 million shares to 3.5 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 4.03 million shares. A decline of -15.29% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.39 of the overall float, the days-to-cover ratio (short ratio) decline to 3.39.
Which companies own the most shares of Neurocrine Biosciences, Inc (NBIX)?
In terms of Neurocrine Biosciences, Inc share price expectations, FactSet research, analysts set an average price target of 158 in the next 12 months, up nearly 20.39% from the previous closing price of $131.24. Analysts anticipate Neurocrine Biosciences, Inc stock to reach 168 by 2025, with the lowest price target being 150. In spite of this, 14 analysts ranked Neurocrine Biosciences, Inc stock as Buy at the end of 2025. On October 10, 2024, Raymond James assigned a price target of “an Outperform” to the stock and resumed coverage with a $155.
